TOP > 外国特許検索 > PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN

PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN

外国特許コード F170009027
整理番号 (S2015-1633-N0)
掲載日 2017年3月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP071899
国際公開番号 WO 2017026276
国際出願日 平成28年7月26日(2016.7.26)
国際公開日 平成29年2月16日(2017.2.16)
優先権データ
  • 特願2015-156726 (2015.8.7) JP
発明の名称 (英語) PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN
発明の概要(英語) In order to establish a means for selectively delivering a large amount of boron to a tumor tissue, provided is a pharmaceutical composition containing a conjugate of a compound represented by formula (I): X-L-Y (in the formula, X represents a group including 10B, L represents a linker, and Y represents a group bound to a lysine residue), and a tumor-accumulative protein having a lysine residue, wherein the molar ratio (mol number of the compound/mol number of the protein) of the compound and protein contained in the composition exceeds 10.
特許請求の範囲(英語) [claim1]
1. Formula (i): X-L-Y (in formula, X (10) displays the basis which contains B, L displays linker, Y displays the basis where it connects with the lysine residue.)So being the medicine composition which includes the conjugation of the chemical compound which is displayed and the tumor accumulation characteristic protein which possesses the lysine residue, mol ratio of the aforementioned chemical compound and the aforementioned protein which are included in the composition (the number of mols of the aforementioned chemical compound/the number of mols of the aforementioned protein) the medicine composition which features that it is the mol ratio which exceeds 10.
[claim2]
2. The tumor accumulation characteristic protein which possesses the lysine residue, in the claim 1 which features that it is [toransuhuerin] the medicine composition of statement.
[claim3]
3. The tumor accumulation characteristic protein which possesses the lysine residue, in the claim 1 which features that it is the albumen the medicine composition of statement.
[claim4]
4. Y in formula (i), the claim either 1 which features that it is the [mareimijiru] basis or the isothiocyanate basis or 3 in one section the medicine composition of statement.
[claim5]
5. X in formula (i), the claim either 1 which features that it is the basis which is induced from the boron cluster or 4 in one section the medicine composition of statement.
[claim6]
6. X in formula (i), the claim either 1 which features that it is the basis which is induced from [kurosododekaboreto], [kurosokaruboran] or [nidokaruboran] or 4 in one section the medicine composition of statement.
[claim7]
7. L in formula (i), the alkylene basis (however, 1 or more of the alkylene basis - CH [2] -, - O-, - S-, - NH-, or - [CO]-DE it is possible to be substituted.)So the claim either 1 which features that it is or 6 in one section the medicine composition of statement.
[claim8]
8. The claim either 1 which features that it is used for boron neutron capture medical therapy or 7 in one section the medicine composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO INSTITUTE OF TECHNOLOGY
  • 発明者(英語)
  • NAKAMURA HIROYUKI
国際特許分類(IPC)
指定国 (WO201726276)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
詳しくお知りになりたい方は下記「問合せ先」まで直接お問合わせください

PAGE TOP

close
close
close
close
close
close